

# BÄR & KARRER ADVISES HELSINN ON ITS AGREEMENT WITH OBERLAND

*Posted on 19 January 2023*



**Categories:** [Deal & transactions](#), [Tax](#)

**Tags:** [Andrea Ziswiler](#), [Aron Liechti](#), [Bär & Karrer](#), [Elena Kumashova](#), [Helsinn](#), [Michel Morelato](#), [Oberland Capital](#), [Paolo Bottini](#), [Slider](#), [Susanne Schreiber](#)



**Helsinn Group**, a fully integrated, global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, has closed a financing agreement with **Oberland Capital Management**. The funding will allow the company to expand the portfolio of late- and commercial-stage oncology and rare disease products.

The Lugano-based group is a fully integrated global biopharma group with a strong focus on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.

**Oberland Capital** is a private investment firm formed in 2013 with assets under management in excess of \$3 billion, focused exclusively on investing in the global healthcare industry and specializing in flexible investment structures customized to meet the specific needs of its transaction partners.

**Bär & Karrer** advised the Helsinn Group on its financing agreement acting as Swiss legal advisor in this transaction. The team was led by partner **Paolo Bottini** (corporate / m&a and tax, pictured left) and associate **Andrea Ziswiler** (corporate / m&a and banking, insurance & finance, pictured right), as

well as **Susanne Schreiber, Elena Kumashova, Michel Morelato** and **Aron Liechti** (all tax).